• Deals this week: Mundipharma, Ligand Pharmaceuticals pharmaceutical-technology
    November 25, 2018
    Kolon Life Sciences dosed the first patient in a Phase III trial for Invossa this month. It is hoping to be granted the US Food and Drug Administration’s (FDA) Disease Modifying Osteoarthritis Drug (DMOAD) label.
  • Deals this week: Mundipharma, Ligand Pharmaceuticals pharmaceutical-technology
    November 25, 2018
    Kolon Life Sciences dosed the first patient in a Phase III trial for Invossa this month. It is hoping to be granted the US Food and Drug Administration’s (FDA) Disease Modifying Osteoarthritis Drug (DMOAD) label.
PharmaSources Customer Service